Reaction
Palmoplantar Pustulosis reporting signals
As of the last recalculation, Palmoplantar Pustulosis appears in 504 FAERS reports alongside 12 co-occurring drug terms. The strongest observed disproportionality signal is ADALIMUMAB-AATY (PRR 82.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Adalimumab-Aaty | 80 | 82.8 | 82.9 |
| Atropine | 16 | 82.3 | 82.5 |
| Adalimumab-Fkjp | 78 | 82.1 | 82.2 |
| Adalimumab-Adaz | 84 | 78.7 | 78.8 |
| Atropine Sulfate | 16 | 63.1 | 63.2 |
| Testosterone | 17 | 31.0 | 31.1 |
| Secukinumab | 85 | 26.0 | 26.0 |
| Apremilast | 57 | 18.0 | 18.0 |
| Ixekizumab | 15 | 17.2 | 17.2 |
| Certolizumab Pegol | 37 | 14.0 | 14.0 |
| Bimekizumab | 6 | 11.8 | 11.8 |
| Guselkumab | 8 | 9.4 | 9.4 |